Jun 24, 2022
Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic modeling and simulation indicated that an 80 mg fixed dose provides similar exposure to the 1.0 mg/kg dose, where
Jun 08, 2022
Oral presentation to include additional durability data from patients treated with NTLA-2001, the first-ever systemically administered in vivo CRISPR investigational therapy Presentation to include data supporting fixed dose selection in the ongoing single-dose expansion cohort of polyneuropathy
May 02, 2022
CAMBRIDGE, Mass. , May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji , R.Ph., to its board of
May 02, 2022
Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading  T cells and deployable for TCR-T and CAR-T cell therapy Findings support recent development candidate initiation of NTLA-6001, an investigational allogeneic CAR-T therapy, for the treatment of
Feb 28, 2022
Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levels Durable serum TTR reductions observed with patient follow-up ranging from 2 to 12 months NTLA-2001 was generally well tolerated